{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T22:05:47Z","timestamp":1794002747515,"version":"4.8.0"},"reference-count":128,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,11,20]],"date-time":"2020-11-20T00:00:00Z","timestamp":1605830400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,11,20]],"date-time":"2020-11-20T00:00:00Z","timestamp":1605830400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Immun Ageing"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Autoimmune hemolytic anemia (AIHA) is an acquired, heterogeneous group of diseases which includes warm AIHA, cold agglutinin disease (CAD), mixed AIHA, paroxysmal cold hemoglobinuria and atypical AIHA. Currently CAD is defined as a chronic, clonal lymphoproliferative disorder, while the presence of cold agglutinins underlying other diseases is known as cold agglutinin syndrome. AIHA is mediated by autoantibodies directed against red blood cells (RBCs) causing premature erythrocyte destruction. The pathogenesis of AIHA is complex and still not fully understood. Recent studies indicate the involvement of T and B cell dysregulation, reduced CD4+ and CD25+ Tregs, increased clonal expansions of CD8\u2009+\u2009T cells, imbalance of Th17\/Tregs and Tfh\/Tfr, and impaired lymphocyte apoptosis. Changes in some RBC membrane structures, under the influence of mechanical stimuli or oxidative stress, may promote autohemolysis. The clinical presentation and treatment of AIHA are influenced by many factors, including the type of AIHA, degree of hemolysis, underlying diseases, presence of concomitant comorbidities, bone marrow compensatory abilities and the presence of fibrosis and dyserthropoiesis. The main treatment for AIHA is based on the inhibition of autoantibody production by mono- or combination therapy using GKS and\/or rituximab and, rarely, immunosuppressive drugs or immunomodulators. Reduction of erythrocyte destruction via splenectomy is currently the third line of treatment for warm AIHA. Supportive treatment including vitamin supplementation, recombinant erythropoietin, thrombosis prophylaxis and the prevention and treatment of infections is essential. New groups of drugs that inhibit immune responses at various levels are being developed intensively, including inhibition of antibody-mediated RBCs phagocytosis, inhibition of B cell and plasma cell frequency and activity, inhibition of IgG recycling, immunomodulation of T lymphocytes function, and complement cascade inhibition. Recent studies have brought about changes in classification and progress in understanding the pathogenesis and treatment of AIHA, although there are still many issues to be resolved, particularly concerning the impact of age-associated changes to immunity.<\/jats:p>","DOI":"10.1186\/s12979-020-00208-7","type":"journal-article","created":{"date-parts":[[2020,11,20]],"date-time":"2020-11-20T05:20:39Z","timestamp":1605849639000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":116,"title":["Autoimmune hemolytic anemia: current knowledge and perspectives"],"prefix":"10.1186","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9361-4401","authenticated-orcid":false,"given":"Sylwia Sulimiera","family":"Michalak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Olewicz-Gawlik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Rupa-Matysek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edyta","family":"Wolny-Rokicka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"El\u017cbieta","family":"Nowakowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lidia","family":"Gil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,11,20]]},"reference":[{"key":"208_CR1","doi-asserted-by":"publisher","first-page":"131","DOI":"10.3389\/fimmu.2013.00131","volume":"4","author":"JJ Goronzy","year":"2013","unstructured":"Goronzy JJ, Li G, Yang Z, Weyand CM. The janus head of T cell aging - autoimmunity and immunodeficiency. Front Immunol. 2013;4:131.","journal-title":"Front Immunol"},{"issue":"10","key":"208_CR2","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1080\/1744666X.2018.1521722","volume":"14","author":"W Barcellini","year":"2018","unstructured":"Barcellini W, Fattizzo B, Zaninoni A. Current and emerging treatment options for autoimmune hemolytic anemia. Expert Rev Clin Immunol. 2018;14(10):857\u201372.","journal-title":"Expert Rev Clin Immunol"},{"key":"208_CR3","doi-asserted-by":"publisher","first-page":"100648","DOI":"10.1016\/j.blre.2019.100648","volume":"41","author":"U J\u00e4ger","year":"2020","unstructured":"J\u00e4ger U, Barcellini W, Broome CM, Gertz MA, Hill A, Hill QA, et al. Diagnosis and treatment of autoimmune hemolytic anemia in adults: Recommendations from the First International Consensus Meeting. Blood Rev. 2020;41:100648.","journal-title":"Blood Rev"},{"issue":"12","key":"208_CR4","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1182\/bloodadvances.2019000036","volume":"3","author":"QA Hill","year":"2019","unstructured":"Hill QA, Hill A, Berentsen S. Defining autoimmune hemolytic anemia: a systematic review of the terminology used for diagnosis and treatment. Blood Adv. 2019;3(12):1897\u2013906.","journal-title":"Blood Adv"},{"issue":"1","key":"208_CR5","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1111\/bjh.16794","volume":"190","author":"G Lazarian","year":"2020","unstructured":"Lazarian G, Quinquenel A, Bellal M, Siavellis J, Jacquy C, Re D, et al. Autoimmune haemolytic anaemia associated with COVID-19 infection. Br J Haematol. 2020;190(1):29\u201331.","journal-title":"Br J Haematol"},{"issue":"4","key":"208_CR6","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1517\/14740338.2012.678832","volume":"11","author":"G Garratty","year":"2012","unstructured":"Garratty G. Immune hemolytic anemia caused by drugs. Expert Opin Drug Saf. 2012;11(4):635\u201342.","journal-title":"Expert Opin Drug Saf"},{"issue":"2","key":"208_CR7","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1111\/bjh.14654","volume":"177","author":"QA Hill","year":"2017","unstructured":"Hill QA, Stamps R, Massey E, Grainger JD, Provan D, Hill A, et al. Guidelines on the management of drug-induced immune and secondary autoimmune, haemolytic anaemia. Br J Haematol. 2017;177(2):208\u201320.","journal-title":"Br J Haematol"},{"issue":"8","key":"208_CR8","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1093\/infdis\/jix384","volume":"216","author":"Y-F Yen","year":"2017","unstructured":"Yen Y-F, Lan Y-C, Huang C-T, Jen I-A, Chen M, Lee C-Y, et al. Human immunodeficiency virus infection increases the risk of incident autoimmune hemolytic Anemia: a population-based cohort study in Taiwan. J Infect Dis. 2017;216(8):1000\u20137.","journal-title":"J Infect Dis"},{"issue":"7","key":"208_CR9","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1056\/NEJMcp1900554","volume":"381","author":"RA Brodsky","year":"2019","unstructured":"Brodsky RA. Warm Autoimmune Hemolytic Anemia. N Engl J Med. 2019;381(7):647\u201354.","journal-title":"N Engl J Med"},{"issue":"7","key":"208_CR10","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1182\/blood-2013-02-474437","volume":"122","author":"PL Swiecicki","year":"2013","unstructured":"Swiecicki PL, Hegerova LT, Gertz MA. Cold agglutinin disease. Blood. 2013;122(7):1114\u201321.","journal-title":"Blood."},{"issue":"4\u20135","key":"208_CR11","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.blre.2010.06.004","volume":"24","author":"G Garratty","year":"2010","unstructured":"Garratty G. Immune hemolytic anemia associated with drug therapy. Blood Rev. 2010 Sep;24(4\u20135):143\u201350.","journal-title":"Blood Rev"},{"key":"208_CR12","doi-asserted-by":"publisher","first-page":"189","DOI":"10.3389\/fimmu.2012.00189","volume":"3","author":"JC Podjasek","year":"2012","unstructured":"Podjasek JC, Abraham RS. Autoimmune cytopenias in common variable immunodeficiency. Front Immunol. 2012;3:189.","journal-title":"Front Immunol"},{"key":"208_CR13","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.12688\/f1000research.11545.1","volume":"6","author":"K Bride","year":"2017","unstructured":"Bride K, Teachey D. Autoimmune lymphoproliferative syndrome: more than a FAScinating disease. F1000Res. 2017;6:1928.","journal-title":"F1000Res"},{"issue":"10","key":"208_CR14","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s11912-019-0838-7","volume":"21","author":"TF Michniacki","year":"2019","unstructured":"Michniacki TF, Ebens CL, Choi SW. Immune-mediated Cytopenias after hematopoietic cell transplantation: pathophysiology, clinical manifestations, diagnosis, and treatment strategies. Curr Oncol Rep. 2019;21(10):87.","journal-title":"Curr Oncol Rep"},{"issue":"4","key":"208_CR15","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1016\/j.bbmt.2017.12.782","volume":"24","author":"MD Kruizinga","year":"2018","unstructured":"Kruizinga MD, van Tol MJD, Bekker V, Netelenbos T, Smiers FJ, Bresters D, et al. Risk factors, treatment, and immune Dysregulation in autoimmune Cytopenia after allogeneic hematopoietic stem cell transplantation in pediatric patients. Biol Blood Marrow Transplant. 2018;24(4):772\u20138.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"15","key":"208_CR16","doi-asserted-by":"publisher","first-page":"6549","DOI":"10.1002\/cam4.2539","volume":"8","author":"W Lv","year":"2019","unstructured":"Lv W, Qu H, Wu M, Fan Z, Huang F, Xu N, et al. Autoimmune hemolytic anemia after allogeneic hematopoietic stem cell transplantation in adults: a southern China multicenter experience. Cancer Med. 2019;8(15):6549\u201358.","journal-title":"Cancer Med"},{"key":"208_CR17","doi-asserted-by":"publisher","first-page":"265","DOI":"10.2147\/JBM.S190327","volume":"10","author":"W Barcellini","year":"2019","unstructured":"Barcellini W, Fattizzo B, Zaninoni A. Management of refractory autoimmune hemolytic anemia after allogeneic hematopoietic stem cell transplantation: current perspectives. J Blood Med. 2019;10:265\u201378.","journal-title":"J Blood Med"},{"key":"208_CR18","doi-asserted-by":"publisher","first-page":"497","DOI":"10.2147\/CLEP.S250250","volume":"12","author":"DL Hansen","year":"2020","unstructured":"Hansen DL, M\u00f6ller S, Andersen K, Gaist D, Frederiksen H. Increasing incidence and prevalence of acquired hemolytic Anemias in Denmark, 1980-2016. Clin Epidemiol. 2020;12:497\u2013508.","journal-title":"Clin Epidemiol"},{"issue":"1","key":"208_CR19","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.blre.2007.08.001","volume":"22","author":"CH Packman","year":"2008","unstructured":"Packman CH. Hemolytic anemia due to warm autoantibodies. Blood Rev. 2008;22(1):17\u201331.","journal-title":"Blood Rev"},{"key":"208_CR20","doi-asserted-by":"publisher","first-page":"93","DOI":"10.2147\/JBM.S177621","volume":"10","author":"S Berentsen","year":"2019","unstructured":"Berentsen S, R\u00f6th A, Randen U, Jilma B, Tj\u00f8nnfjord GE. Cold agglutinin disease: current challenges and future prospects. J Blood Med. 2019;10:93\u2013103.","journal-title":"J Blood Med"},{"issue":"6281","key":"208_CR21","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1136\/bmj.282.6281.2023","volume":"282","author":"RJ Sokol","year":"1981","unstructured":"Sokol RJ, Hewitt S, Stamps BK. Autoimmune haemolysis: an 18-year study of 865 cases referred to a regional transfusion Centre. Br Med J (Clin Res Ed). 1981;282(6281):2023\u20137.","journal-title":"Br Med J (Clin Res Ed)"},{"issue":"4","key":"208_CR22","first-page":"460","volume":"91","author":"S Berentsen","year":"2006","unstructured":"Berentsen S, Ulvestad E, Langholm R, Beiske K, Hjorth-Hansen H, Ghanima W, et al. Primary chronic cold agglutinin disease: a population based clinical study of 86 patients. Haematologica. 2006;91(4):460\u20136.","journal-title":"Haematologica."},{"issue":"4","key":"208_CR23","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1111\/j.1423-0410.1990.tb05000.x","volume":"58","author":"B G\u00f6ttsche","year":"1990","unstructured":"G\u00f6ttsche B, Salama A, Mueller-Eckhardt C. Donath-Landsteiner autoimmune hemolytic anemia in children. A study of 22 cases. Vox Sang. 1990;58(4):281\u20136.","journal-title":"Vox Sang"},{"key":"208_CR24","first-page":"2018","volume":"13","author":"R Leibrandt","year":"2018","unstructured":"Leibrandt R, Angelino K, Vizel-Schwartz M, Shapira I. Paroxysmal Cold Hemoglobinuria in an Adult with Respiratory Syncytial Virus. Case Rep Hematol. 2018;13:2018 Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC6257899\/.","journal-title":"Case Rep Hematol"},{"key":"208_CR25","doi-asserted-by":"publisher","first-page":"271","DOI":"10.3389\/fimmu.2013.00271","volume":"4","author":"T F\u00fcl\u00f6p","year":"2013","unstructured":"F\u00fcl\u00f6p T, Larbi A, Pawelec G. Human T cell aging and the impact of persistent viral infections. Front Immunol. 2013;4:271.","journal-title":"Front Immunol"},{"issue":"24","key":"208_CR26","doi-asserted-by":"publisher","first-page":"3731","DOI":"10.1182\/blood-2014-11-610907","volume":"125","author":"T Wada","year":"2015","unstructured":"Wada T, Koyama D, Kikuchi J, Honda H, Furukawa Y. Overexpression of the shortest isoform of histone demethylase LSD1 primes hematopoietic stem cells for malignant transformation. Blood. 2015;125(24):3731\u201346.","journal-title":"Blood."},{"key":"208_CR27","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.arr.2017.01.002","volume":"35","author":"GP Gusev","year":"2017","unstructured":"Gusev GP, Govekar R, Gadewal N, Agalakova NI. Understanding quasi-apoptosis of the most numerous enucleated components of blood needs detailed molecular autopsy. Ageing Res Rev. 2017;35:46\u201362.","journal-title":"Ageing Res Rev"},{"issue":"2","key":"208_CR28","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1159\/000430137","volume":"36","author":"A Lupescu","year":"2015","unstructured":"Lupescu A, Bissinger R, Goebel T, Salker MS, Alzoubi K, Liu G, et al. Enhanced suicidal erythrocyte death contributing to anemia in the elderly. Cell Physiol Biochem. 2015;36(2):773\u201383.","journal-title":"Cell Physiol Biochem"},{"key":"208_CR29","doi-asserted-by":"crossref","unstructured":"Barcellini W, Giannotta J, Fattizzo B. Autoimmune hemolytic anemia in adults: primary risk factors and diagnostic procedures. Expert Rev Hematol. 2020;13(6):585\u201397.","DOI":"10.1080\/17474086.2020.1754791"},{"issue":"9","key":"208_CR30","doi-asserted-by":"publisher","first-page":"E150","DOI":"10.1002\/ajh.23767","volume":"89","author":"M Roumier","year":"2014","unstructured":"Roumier M, Loustau V, Guillaud C, Languille L, Mahevas M, Khellaf M, et al. Characteristics and outcome of warm autoimmune hemolytic anemia in adults: new insights based on a single-center experience with 60 patients. Am J Hematol. 2014;89(9):E150\u20135.","journal-title":"Am J Hematol"},{"issue":"9","key":"208_CR31","doi-asserted-by":"publisher","first-page":"E243","DOI":"10.1002\/ajh.25212","volume":"93","author":"W Barcellini","year":"2018","unstructured":"Barcellini W, Zaninoni A, Fattizzo B, Giannotta JA, Lunghi M, Ferrari A, et al. Predictors of refractoriness to therapy and healthcare resource utilization in 378 patients with primary autoimmune hemolytic anemia from eight Italian reference centers. Am J Hematol. 2018;93(9):E243\u20136.","journal-title":"Am J Hematol"},{"issue":"19","key":"208_CR32","doi-asserted-by":"publisher","first-page":"2930","DOI":"10.1182\/blood-2014-06-583021","volume":"124","author":"W Barcellini","year":"2014","unstructured":"Barcellini W, Fattizzo B, Zaninoni A, Radice T, Nichele I, Di Bona E, et al. Clinical heterogeneity and predictors of outcome in primary autoimmune hemolytic anemia: a GIMEMA study of 308 patients. Blood. 2014;124(19):2930\u20136.","journal-title":"Blood."},{"issue":"3","key":"208_CR33","first-page":"496","volume":"45","author":"PJ Russell","year":"1981","unstructured":"Russell PJ, Cunningham J, Dunkley M, Wilkinson NM. The role of suppressor T cells in the expression of autoimmune haemolytic anaemia in NZB mice. Clin Exp Immunol. 1981;45(3):496\u2013503.","journal-title":"Clin Exp Immunol"},{"issue":"7","key":"208_CR34","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1016\/j.freeradbiomed.2010.01.012","volume":"48","author":"Y Iuchi","year":"2010","unstructured":"Iuchi Y, Kibe N, Tsunoda S, Suzuki S, Mikami T, Okada F, et al. Implication of oxidative stress as a cause of autoimmune hemolytic anemia in NZB mice. Free Radic Biol Med. 2010;48(7):935\u201344.","journal-title":"Free Radic Biol Med"},{"issue":"9","key":"208_CR35","doi-asserted-by":"publisher","first-page":"3746","DOI":"10.1182\/blood-2004-12-4692","volume":"105","author":"A Mqadmi","year":"2005","unstructured":"Mqadmi A, Zheng X, Yazdanbakhsh K. CD4+CD25+ regulatory T cells control induction of autoimmune hemolytic anemia. Blood. 2005;105(9):3746\u20138.","journal-title":"Blood."},{"key":"208_CR36","doi-asserted-by":"publisher","first-page":"348","DOI":"10.3389\/fimmu.2016.00348","volume":"7","author":"AL Richards","year":"2016","unstructured":"Richards AL, Kapp LM, Wang X, Howie HL, Hudson KE. Regulatory T cells are dispensable for tolerance to RBC antigens. Front Immunol. 2016;7:348.","journal-title":"Front Immunol"},{"issue":"6","key":"208_CR37","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1097\/MOH.0000000000000459","volume":"25","author":"HL Howie","year":"2018","unstructured":"Howie HL, Hudson KE. Murine models of autoimmune hemolytic anemia. Curr Opin Hematol. 2018;25(6):473\u201381.","journal-title":"Curr Opin Hematol"},{"issue":"11","key":"208_CR38","doi-asserted-by":"publisher","first-page":"e0166878","DOI":"10.1371\/journal.pone.0166878","volume":"11","author":"S Chatterjee","year":"2016","unstructured":"Chatterjee S, Bhardwaj N, Saxena RK. Identification of stages of Erythroid differentiation in bone marrow and erythrocyte subpopulations in blood circulation that are preferentially lost in autoimmune hemolytic Anemia in mouse. PLoS One. 2016;11(11):e0166878.","journal-title":"PLoS One"},{"key":"208_CR39","volume-title":"Binding of autoantibodies and apoptotic response in erythroid cells in the mouse model of autoimmune hemolytic anemia","author":"S Chatterjee","year":"2017","unstructured":"Chatterjee S, Saxena RK. Binding of autoantibodies and apoptotic response in erythroid cells in the mouse model of autoimmune hemolytic anemia; 2017."},{"issue":"12","key":"208_CR40","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1016\/j.exphem.2012.08.008","volume":"40","author":"L Xu","year":"2012","unstructured":"Xu L, Zhang T, Liu Z, Li Q, Xu Z, Ren T. Critical role of Th17 cells in development of autoimmune hemolytic anemia. Exp Hematol. 2012;40(12):994\u20131004 e4.","journal-title":"Exp Hematol"},{"key":"208_CR41","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.bcmd.2016.06.006","volume":"61","author":"X Yao","year":"2016","unstructured":"Yao X, Li C, Yang J, Wang G, Li C, Xia Y. Differences in frequency and regulation of T follicular helper cells between newly diagnosed and chronic pediatric immune thrombocytopenia. Blood Cells Mol Dis. 2016;61:26\u201336.","journal-title":"Blood Cells Mol Dis"},{"key":"208_CR42","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.biopha.2015.07.022","volume":"75","author":"Burenbatu","year":"2015","unstructured":"Burenbatu, Borjigin M, Eerdunduleng, Huo W, Gong C, Hasengaowa, et al. Profiling of miRNA expression in immune thrombocytopenia patients before and after Qishunbaolier (QSBLE) treatment. Biomed Pharmacother. 2015;75:196\u2013204.","journal-title":"Biomed Pharmacother"},{"key":"208_CR43","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.cca.2016.01.028","volume":"455","author":"H-W Zhang","year":"2016","unstructured":"Zhang H-W, Zhou P, Wang K-Z, Liu J-B, Huang Y-S, Tu Y-T, et al. Platelet proteomics in diagnostic differentiation of primary immune thrombocytopenia using SELDI-TOF-MS. Clin Chim Acta. 2016;455:75\u20139.","journal-title":"Clin Chim Acta"},{"issue":"1","key":"208_CR44","doi-asserted-by":"publisher","first-page":"19767","DOI":"10.1038\/s41598-019-56365-3","volume":"9","author":"Y Gao","year":"2019","unstructured":"Gao Y, Jin H, Nan D, Yu W, Zhang J, Yang Y, et al. The role of T follicular helper cells and T follicular regulatory cells in the pathogenesis of autoimmune hemolytic Anemia. Sci Rep. 2019;9(1):19767.","journal-title":"Sci Rep"},{"issue":"3","key":"208_CR45","doi-asserted-by":"publisher","first-page":"147","DOI":"10.3109\/08916934.2016.1138219","volume":"49","author":"SJ Smirnova","year":"2016","unstructured":"Smirnova SJ, Sidorova JV, Tsvetaeva NV, Nikulina OF, Biderman BV, Nikulina EE, et al. Expansion of CD8+ cells in autoimmune hemolytic anemia. Autoimmunity. 2016;49(3):147\u201354.","journal-title":"Autoimmunity."},{"issue":"6","key":"208_CR46","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1093\/infdis\/jir433","volume":"204","author":"A Tsiakalos","year":"2011","unstructured":"Tsiakalos A, Routsias JG, Kordossis T, Moutsopoulos HM, Tzioufas AG, Sipsas NV. Fine epitope specificity of anti-erythropoietin antibodies reveals molecular mimicry with HIV-1 p17 protein: a pathogenetic mechanism for HIV-1-related anemia. J Infect Dis. 2011;204(6):902\u201311.","journal-title":"J Infect Dis"},{"issue":"1","key":"208_CR47","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1086\/595013","volume":"48","author":"V Martinez","year":"2009","unstructured":"Martinez V, Diemert M-C, Braibant M, Potard V, Charuel J-L, Barin F, et al. Anticardiolipin antibodies in HIV infection are independently associated with antibodies to the membrane proximal external region of gp41 and with cell-associated HIV DNA and immune activation. Clin Infect Dis. 2009;48(1):123\u201332.","journal-title":"Clin Infect Dis"},{"key":"208_CR48","doi-asserted-by":"crossref","unstructured":"Barcellini W, Fattizzo B. The Changing Landscape of Autoimmune Hemolytic Anemia. Front Immunol. 2020;11:946. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC7325906\/.","DOI":"10.3389\/fimmu.2020.00946"},{"key":"208_CR49","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.3389\/fonc.2019.01435","volume":"9","author":"B Fattizzo","year":"2019","unstructured":"Fattizzo B, Barcellini W. Autoimmune Cytopenias in chronic lymphocytic leukemia: focus on molecular aspects. Front Oncol. 2019;9:1435.","journal-title":"Front Oncol"},{"key":"208_CR50","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.3389\/fimmu.2019.01193","volume":"10","author":"A Lisco","year":"2019","unstructured":"Lisco A, Wong C-S, Price S, Ye P, Niemela J, Anderson M, et al. Paradoxical CD4 Lymphopenia in autoimmune Lymphoproliferative syndrome (ALPS). Front Immunol. 2019;10:1193.","journal-title":"Front Immunol"},{"issue":"3","key":"208_CR51","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.clim.2008.02.013","volume":"128","author":"S S\u00e1nchez-Ram\u00f3n","year":"2008","unstructured":"S\u00e1nchez-Ram\u00f3n S, Radigan L, Yu JE, Bard S, Cunningham-Rundles C. Memory B cells in common variable immunodeficiency: clinical associations and sex differences. Clin Immunol. 2008;128(3):314\u201321.","journal-title":"Clin Immunol"},{"issue":"2","key":"208_CR52","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1042\/BJ20061386","volume":"402","author":"Y Iuchi","year":"2007","unstructured":"Iuchi Y, Okada F, Onuma K, Onoda T, Asao H, Kobayashi M, et al. Elevated oxidative stress in erythrocytes due to a SOD1 deficiency causes anaemia and triggers autoantibody production. Biochem J. 2007;402(2):219\u201327.","journal-title":"Biochem J"},{"issue":"11","key":"208_CR53","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1016\/j.freeradbiomed.2005.07.002","volume":"39","author":"RM Johnson","year":"2005","unstructured":"Johnson RM, Goyette G, Ravindranath Y, Ho Y-S. Hemoglobin autoxidation and regulation of endogenous H2O2 levels in erythrocytes. Free Radic Biol Med. 2005;39(11):1407\u201317.","journal-title":"Free Radic Biol Med"},{"issue":"7","key":"208_CR54","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1080\/10715762.2016.1178388","volume":"50","author":"N Otsuki","year":"2016","unstructured":"Otsuki N, Konno T, Kurahashi T, Suzuki S, Lee J, Okada F, et al. The SOD1 transgene expressed in erythroid cells alleviates fatal phenotype in congenic NZB\/NZW-F1 mice. Free Radic Res. 2016;50(7):793\u2013800.","journal-title":"Free Radic Res"},{"issue":"3","key":"208_CR55","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1097\/MOH.0000000000000423","volume":"25","author":"H Zhong","year":"2018","unstructured":"Zhong H, Yazdanbakhsh K. Hemolysis and immune regulation. Curr Opin Hematol. 2018;25(3):177\u201382.","journal-title":"Curr Opin Hematol"},{"issue":"1","key":"208_CR56","doi-asserted-by":"publisher","first-page":"19443","DOI":"10.1038\/s41598-019-55924-y","volume":"9","author":"JP Buerck","year":"2019","unstructured":"Buerck JP, Burke DK, Schmidtke DW, Snyder TA, Papavassiliou D, O\u2019Rear EA. A Flow Induced Autoimmune Response and Accelerated Senescence of Red Blood Cells in Cardiovascular Devices. Sci Rep. 2019;9(1):19443.","journal-title":"Sci Rep"},{"key":"208_CR57","doi-asserted-by":"crossref","unstructured":"Leal JKF, Adjobo-Hermans MJW, Bosman GJCGM. Red Blood Cell Homeostasis: Mechanisms and Effects of Microvesicle Generation in Health and Disease. Front Physiol. 2018;9:703. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC6002509\/.","DOI":"10.3389\/fphys.2018.00703"},{"issue":"9","key":"208_CR58","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1111\/j.1537-2995.2008.01794.x","volume":"48","author":"AG Kriebardis","year":"2008","unstructured":"Kriebardis AG, Antonelou MH, Stamoulis KE, Economou-Petersen E, Margaritis LH, Papassideri IS. RBC-derived vesicles during storage: ultrastructure, protein composition, oxidation, and signaling components. Transfusion. 2008;48(9):1943\u201353.","journal-title":"Transfusion."},{"key":"208_CR59","unstructured":"Gao Y, Jin H, Tan H, Wang Y, Wu J, Wang Y, et al. The role of extracellular vesicles from stored RBC units in B lymphocyte survival and plasma cell differentiation. J Leukoc Biol. Available from: https:\/\/jlb.onlinelibrary.wiley.com\/doi\/abs\/10.1002\/JLB.1A0220-666R."},{"issue":"2","key":"208_CR60","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1111\/j.1365-2141.1995.tb05315.x","volume":"91","author":"L Michaux","year":"1995","unstructured":"Michaux L, Dierlamm J, Wlodarska I, Stul M, Bosly A, Delannoy A, et al. Trisomy 3 is a consistent chromosome change in malignant lymphoproliferative disorders preceded by cold agglutinin disease. Br J Haematol. 1995;91(2):421\u20134.","journal-title":"Br J Haematol"},{"issue":"5","key":"208_CR61","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1111\/bjh.15063","volume":"183","author":"A Ma\u0142ecka","year":"2018","unstructured":"Ma\u0142ecka A, Tr\u00f8en G, Tierens A, \u00d8stlie I, Ma\u0142ecki J, Randen U, et al. Frequent somatic mutations of KMT2D (MLL2) and CARD11 genes in primary cold agglutinin disease. Br J Haematol. 2018;183(5):838\u201342.","journal-title":"Br J Haematol"},{"issue":"6","key":"208_CR62","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1182\/bloodadvances.2020001608","volume":"4","author":"A Ma\u0142ecka","year":"2020","unstructured":"Ma\u0142ecka A, Delabie J, \u00d8stlie I, Tierens A, Randen U, Berentsen S, et al. Cold agglutinin\u2013associated B-cell lymphoproliferative disease shows highly recurrent gains of chromosome 3 and 12 or 18. Blood Adv. 2020;4(6):993\u20136.","journal-title":"Blood Adv"},{"key":"208_CR63","doi-asserted-by":"publisher","first-page":"406","DOI":"10.12688\/f1000research.13826.1","volume":"7","author":"F Bertoni","year":"2018","unstructured":"Bertoni F, Rossi D, Zucca E. Recent advances in understanding the biology of marginal zone lymphoma. F1000Res. 2018;7:406.","journal-title":"F1000Res"},{"issue":"7","key":"208_CR64","doi-asserted-by":"publisher","first-page":"3777","DOI":"10.4049\/jimmunol.169.7.3777","volume":"169","author":"KN Potter","year":"2002","unstructured":"Potter KN, Hobby P, Klijn S, Stevenson FK, Sutton BJ. Evidence for involvement of a hydrophobic patch in framework region 1 of human V4-34-encoded Igs in recognition of the red blood cell I antigen. J Immunol. 2002;169(7):3777\u201382.","journal-title":"J Immunol"},{"issue":"6","key":"208_CR65","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1517\/14728222.2015.1016499","volume":"19","author":"Y Hu","year":"2015","unstructured":"Hu Y, Wang X, Yu S, Hou Y, Ma D, Hou M. Neutralizations of IL-17A and IL-21 regulate regulatory T cell\/T-helper 17 imbalance via T-helper 17-associated signaling pathway in immune thrombocytopenia. Expert Opin Ther Targets. 2015;19(6):723\u201332.","journal-title":"Expert Opin Ther Targets"},{"issue":"12","key":"208_CR66","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1038\/nm.1888","volume":"14","author":"PB Yu","year":"2008","unstructured":"Yu PB, Deng DY, Lai CS, Hong CC, Cuny GD, Bouxsein ML, et al. BMP type I receptor inhibition reduces heterotopic ossification. Nat Med. 2008;14(12):1363\u20139.","journal-title":"Nat Med"},{"issue":"5","key":"208_CR67","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1097\/CCO.0b013e328348c683","volume":"23","author":"P Strati","year":"2011","unstructured":"Strati P, Caligaris-Cappio F. A matter of debate in chronic lymphocytic leukemia: is the occurrence of autoimmune disorders an indicator of chronic lymphocytic leukemia therapy? Curr Opin Oncol. 2011;23(5):455\u201360.","journal-title":"Curr Opin Oncol"},{"issue":"9","key":"208_CR68","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.3324\/haematol.10975","volume":"92","author":"C Grandjenette","year":"2007","unstructured":"Grandjenette C, Kennel A, Faure GC, B\u00e9n\u00e9 MC, Feugier P. Expression of functional toll-like receptors by B-chronic lymphocytic leukemia cells. Haematologica. 2007;92(9):1279\u201381.","journal-title":"Haematologica."},{"issue":"9","key":"208_CR69","doi-asserted-by":"publisher","first-page":"2016","DOI":"10.3109\/10428194.2012.763123","volume":"54","author":"G Ferrer","year":"2013","unstructured":"Ferrer G, Navarro A, Hodgson K, Aymerich M, Pereira A, Baumann T, et al. MicroRNA expression in chronic lymphocytic leukemia developing autoimmune hemolytic anemia. Leuk Lymphoma. 2013;54(9):2016\u201322.","journal-title":"Leuk Lymphoma"},{"issue":"10","key":"208_CR70","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1080\/10428190903115410","volume":"50","author":"M Muzio","year":"2009","unstructured":"Muzio M, Bertilaccio MTS, Simonetti G, Frenquelli M, Caligaris-Cappio F. The role of toll-like receptors in chronic B-cell malignancies. Leuk Lymphoma. 2009;50(10):1573\u201380.","journal-title":"Leuk Lymphoma"},{"issue":"8","key":"208_CR71","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.3109\/10428194.2013.856426","volume":"55","author":"W Barcellini","year":"2014","unstructured":"Barcellini W, Imperiali FG, Zaninoni A, Reda G, Consonni D, Fattizzo B, et al. Toll-like receptor 4 and 9 expression in B-chronic lymphocytic leukemia: relationship with infections, autoimmunity and disease progression. Leuk Lymphoma. 2014;55(8):1768\u201373.","journal-title":"Leuk Lymphoma"},{"key":"208_CR72","doi-asserted-by":"publisher","first-page":"363278","DOI":"10.1155\/2015\/363278","volume":"2015","author":"S Berentsen","year":"2015","unstructured":"Berentsen S, Sundic T. Red blood cell destruction in autoimmune hemolytic anemia: role of complement and potential new targets for therapy. Biomed Res Int. 2015;2015:363278.","journal-title":"Biomed Res Int"},{"issue":"1","key":"208_CR73","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1182\/asheducation-2018.1.382","volume":"2018","author":"A Hill","year":"2018","unstructured":"Hill A, Hill QA. Autoimmune hemolytic anemia. Hematology Am Soc Hematol Educ Program. 2018;2018(1):382\u20139.","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"208_CR74","doi-asserted-by":"publisher","first-page":"590","DOI":"10.3389\/fimmu.2020.00590","volume":"11","author":"S Berentsen","year":"2020","unstructured":"Berentsen S. New insights in the pathogenesis and therapy of cold agglutinin-mediated autoimmune hemolytic Anemia. Front Immunol. 2020;11:590.","journal-title":"Front Immunol"},{"issue":"26","key":"208_CR75","doi-asserted-by":"publisher","first-page":"4010","DOI":"10.1182\/blood-2014-04-568733","volume":"123","author":"S Berentsen","year":"2014","unstructured":"Berentsen S. Complement, cold agglutinins, and therapy. Blood. 2014;123(26):4010\u20132.","journal-title":"Blood."},{"issue":"1\u20132","key":"208_CR76","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/S0955-3886(00)00033-3","volume":"22","author":"FP McNicholl","year":"2000","unstructured":"McNicholl FP. Clinical syndromes associated with cold agglutinins. Transfus Sci. 2000;22(1\u20132):125\u201333.","journal-title":"Transfus Sci"},{"issue":"3","key":"208_CR77","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1111\/bjh.14478","volume":"176","author":"QA Hill","year":"2017","unstructured":"Hill QA, Stamps R, Massey E, Grainger JD, Provan D, Hill A, et al. The diagnosis and management of primary autoimmune haemolytic anaemia. Br J Haematol. 2017;176(3):395\u2013411.","journal-title":"Br J Haematol"},{"issue":"3","key":"208_CR78","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.hoc.2015.01.004","volume":"29","author":"S Shanbhag","year":"2015","unstructured":"Shanbhag S, Spivak J. Paroxysmal cold hemoglobinuria. Hematol Oncol Clin North Am. 2015 Jun;29(3):473\u20138.","journal-title":"Hematol Oncol Clin North Am"},{"issue":"3","key":"208_CR79","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1309\/LMWD51B2KIFSBLBJ","volume":"45","author":"SN Slemp","year":"2014","unstructured":"Slemp SN, Davisson SM, Slayten J, Cipkala DA, Waxman DA. Two case studies and a review of paroxysmal cold hemoglobinuria. Lab Med. 2014;45(3):253\u20138 quiz e92.","journal-title":"Lab Med"},{"key":"208_CR80","doi-asserted-by":"publisher","unstructured":"Barcellini W, Fattizzo B. Clinical applications of hemolytic markers in the differential diagnosis and Management of Hemolytic Anemia. Dis Markers. 2015;2015:635670. Available from: https:\/\/doi.org\/10.1155\/2015\/635670.","DOI":"10.1155\/2015\/635670"},{"issue":"11","key":"208_CR81","doi-asserted-by":"publisher","first-page":"e0207218","DOI":"10.1371\/journal.pone.0207218","volume":"13","author":"S Audia","year":"2018","unstructured":"Audia S, Bach B, Samson M, Lakomy D, Bour J-B, Burlet B, et al. Venous thromboembolic events during warm autoimmune hemolytic anemia. PLoS One. 2018;13(11):e0207218.","journal-title":"PLoS One"},{"issue":"3","key":"208_CR82","doi-asserted-by":"publisher","first-page":"497","DOI":"10.3324\/haematol.2013.091702","volume":"99","author":"U Randen","year":"2014","unstructured":"Randen U, Tr\u00f8en G, Tierens A, Steen C, Warsame A, Beiske K, et al. Primary cold agglutinin-associated lymphoproliferative disease: a B-cell lymphoma of the bone marrow distinct from lymphoplasmacytic lymphoma. Haematologica. 2014;99(3):497\u2013504.","journal-title":"Haematologica."},{"issue":"4","key":"208_CR83","doi-asserted-by":"publisher","first-page":"E88","DOI":"10.1002\/ajh.25020","volume":"93","author":"B Fattizzo","year":"2018","unstructured":"Fattizzo B, Zaninoni A, Gianelli U, Zanella A, Cortelezzi A, Kulasekararaj AG, et al. Prognostic impact of bone marrow fibrosis and dyserythropoiesis in autoimmune hemolytic anemia. Am J Hematol. 2018;93(4):E88\u201391.","journal-title":"Am J Hematol"},{"key":"208_CR84","doi-asserted-by":"crossref","unstructured":"Fattizzo B, Giannotta J, Zaninoni A, Kulasekararaj A, Cro L, Barcellini W. Small Paroxysmal Nocturnal Hemoglobinuria Clones in Autoimmune Hemolytic Anemia: Clinical Implications and Different Cytokine Patterns in Positive and Negative Patients. Front Immunol. 2020;11:1006. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC7287021\/.","DOI":"10.3389\/fimmu.2020.01006"},{"key":"208_CR85","doi-asserted-by":"publisher","unstructured":"Fattizzo B, Michel M, Zaninoni A, Giannotta J, Guillet S, Frederiksen H, et al. Efficacy of recombinant erythropoietin in autoimmune haemolytic anaemia: a multicentre international study. Haematologica, haematol. 2020. Available from: https:\/\/doi.org\/10.3324\/haematol.2020.250522.","DOI":"10.3324\/haematol.2020.250522"},{"issue":"8","key":"208_CR86","doi-asserted-by":"publisher","first-page":"2925","DOI":"10.1182\/blood-2003-10-3597","volume":"103","author":"S Berentsen","year":"2004","unstructured":"Berentsen S, Ulvestad E, Gjertsen BT, Hjorth-Hansen H, Langholm R, Knutsen H, et al. Rituximab for primary chronic cold agglutinin disease: a prospective study of 37 courses of therapy in 27 patients. Blood. 2004;103(8):2925\u20138.","journal-title":"Blood."},{"issue":"3","key":"208_CR87","doi-asserted-by":"publisher","first-page":"212","DOI":"10.7861\/clinmedicine.18-3-212","volume":"18","author":"A Koffas","year":"2018","unstructured":"Koffas A, Dolman GE, Kennedy PT. Hepatitis B virus reactivation in patients treated with immunosuppressive drugs: a practical guide for clinicians. Clin Med (Lond). 2018;18(3):212\u20138.","journal-title":"Clin Med (Lond)"},{"issue":"11","key":"208_CR88","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1182\/blood-2010-03-259325","volume":"116","author":"K Lechner","year":"2010","unstructured":"Lechner K, J\u00e4ger U. How I treat autoimmune hemolytic anemias in adults. Blood. 2010;116(11):1831\u20138.","journal-title":"Blood."},{"issue":"15","key":"208_CR89","doi-asserted-by":"publisher","first-page":"4036","DOI":"10.1182\/blood-2011-05-347708","volume":"118","author":"M Crowther","year":"2011","unstructured":"Crowther M, Chan YLT, Garbett IK, Lim W, Vickers MA, Crowther MA. Evidence-based focused review of the treatment of idiopathic warm immune hemolytic anemia in adults. Blood. 2011;118(15):4036\u201340.","journal-title":"Blood."},{"issue":"1","key":"208_CR90","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1002\/ajh.24570","volume":"92","author":"M Michel","year":"2017","unstructured":"Michel M, Terriou L, Roudot-Thoraval F, Hamidou M, Ebbo M, Le Guenno G, et al. A randomized and double-blind controlled trial evaluating the safety and efficacy of rituximab for warm auto-immune hemolytic anemia in adults (the RAIHA study). Am J Hematol. 2017;92(1):23\u20137.","journal-title":"Am J Hematol"},{"issue":"3","key":"208_CR91","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1111\/bjh.12541","volume":"163","author":"H Birgens","year":"2013","unstructured":"Birgens H, Frederiksen H, Hasselbalch HC, Rasmussen IH, Nielsen OJ, Kjeldsen L, et al. A phase III randomized trial comparing glucocorticoid monotherapy versus glucocorticoid and rituximab in patients with autoimmune haemolytic anaemia. Br J Haematol. 2013;163(3):393\u20139.","journal-title":"Br J Haematol"},{"key":"208_CR92","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s40164-020-00163-5","volume":"9","author":"S-H Chao","year":"2020","unstructured":"Chao S-H, Chang Y-L, Yen J-C, Liao H-T, Wu T-H, Yu C-L, et al. Efficacy and safety of rituximab in autoimmune and microangiopathic hemolytic anemia: a systematic review and meta-analysis. Exp Hematol Oncol. 2020;9:6.","journal-title":"Exp Hematol Oncol"},{"issue":"16","key":"208_CR93","doi-asserted-by":"publisher","first-page":"3691","DOI":"10.1182\/blood-2011-06-363556","volume":"119","author":"W Barcellini","year":"2012","unstructured":"Barcellini W, Zaja F, Zaninoni A, Imperiali FG, Battista ML, Di Bona E, et al. Low-dose rituximab in adult patients with idiopathic autoimmune hemolytic anemia: clinical efficacy and biologic studies. Blood. 2012;119(16):3691\u20137.","journal-title":"Blood."},{"issue":"4","key":"208_CR94","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.autrev.2014.11.014","volume":"14","author":"Q Reynaud","year":"2015","unstructured":"Reynaud Q, Durieu I, Dutertre M, Ledochowski S, Durupt S, Michallet A-S, et al. Efficacy and safety of rituximab in auto-immune hemolytic anemia: a meta-analysis of 21 studies. Autoimmun Rev. 2015;14(4):304\u201313.","journal-title":"Autoimmun Rev"},{"issue":"9","key":"208_CR95","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1182\/blood-2018-12-885228","volume":"133","author":"B Fattizzo","year":"2019","unstructured":"Fattizzo B, Zaninoni A, Pettine L, Cavallaro F, Di Bona E, Barcellini W. Low-dose rituximab in autoimmune hemolytic anemia: 10 years after. Blood. 2019;133(9):996\u20138.","journal-title":"Blood."},{"issue":"5","key":"208_CR96","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1007\/s00277-016-2605-2","volume":"95","author":"K Laribi","year":"2016","unstructured":"Laribi K, Bolle D, Ghnaya H, Sandu A, Besan\u00e7on A, Denizon N, et al. Rituximab is an effective and safe treatment of relapse in elderly patients with resistant warm AIHA. Ann Hematol. 2016;95(5):765\u20139.","journal-title":"Ann Hematol"},{"issue":"5","key":"208_CR97","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1001\/archsurg.1985.01390290099017","volume":"120","author":"WW Coon","year":"1985","unstructured":"Coon WW. Splenectomy in the treatment of hemolytic anemia. Arch Surg. 1985;120(5):625\u20138.","journal-title":"Arch Surg"},{"issue":"6","key":"208_CR98","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1016\/j.amjsurg.2012.05.030","volume":"204","author":"NY Patel","year":"2012","unstructured":"Patel NY, Chilsen AM, Mathiason MA, Kallies KJ, Bottner WA. Outcomes and complications after splenectomy for hematologic disorders. Am J Surg. 2012;204(6):1014\u20139 discussion 1019-1020.","journal-title":"Am J Surg"},{"issue":"3","key":"208_CR99","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.blre.2017.01.001","volume":"31","author":"J Sys","year":"2017","unstructured":"Sys J, Provan D, Schauwvlieghe A, Vanderschueren S, Dierickx D. The role of splenectomy in autoimmune hematological disorders: outdated or still worth considering? Blood Rev. 2017;31(3):159\u201372.","journal-title":"Blood Rev"},{"issue":"6","key":"208_CR100","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1080\/10428190902887563","volume":"50","author":"M Kaufman","year":"2009","unstructured":"Kaufman M, Limaye SA, Driscoll N, Johnson C, Caramanica A, Lebowicz Y, et al. A combination of rituximab, cyclophosphamide and dexamethasone effectively treats immune cytopenias of chronic lymphocytic leukemia. Leuk Lymphoma. 2009;50(6):892\u20139.","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"208_CR101","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1080\/10428190500286481","volume":"47","author":"C Sch\u00f6llkopf","year":"2006","unstructured":"Sch\u00f6llkopf C, Kjeldsen L, Bjerrum OW, Mourits-Andersen HT, Nielsen JL, Christensen BE, et al. Rituximab in chronic cold agglutinin disease: a prospective study of 20 patients. Leuk Lymphoma. 2006;47(2):253\u201360.","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"208_CR102","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1182\/blood-2017-04-778175","volume":"130","author":"S Berentsen","year":"2017","unstructured":"Berentsen S, Randen U, Oksman M, Birgens H, Tvedt THA, Dalgaard J, et al. Bendamustine plus rituximab for chronic cold agglutinin disease: results of a Nordic prospective multicenter trial. Blood. 2017;130(4):537\u201341.","journal-title":"Blood"},{"issue":"17","key":"208_CR103","doi-asserted-by":"publisher","first-page":"3180","DOI":"10.1182\/blood-2010-06-288647","volume":"116","author":"S Berentsen","year":"2010","unstructured":"Berentsen S, Randen U, V\u00e5gan AM, Hjorth-Hansen H, Vik A, Dalgaard J, et al. High response rate and durable remissions following fludarabine and rituximab combination therapy for chronic cold agglutinin disease. Blood. 2010;116(17):3180\u20134.","journal-title":"Blood."},{"issue":"19","key":"208_CR104","doi-asserted-by":"publisher","first-page":"2543","DOI":"10.1182\/bloodadvances.2018024190","volume":"2","author":"A R\u00f6th","year":"2018","unstructured":"R\u00f6th A, Bommer M, H\u00fcttmann A, Herich-Terh\u00fcrne D, Kuklik N, Rekowski J, et al. Eculizumab in cold agglutinin disease (DECADE): an open-label, prospective, bicentric, nonrandomized phase 2 trial. Blood Adv. 2018;2(19):2543\u20139.","journal-title":"Blood Adv"},{"issue":"4","key":"208_CR105","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1007\/s00277-018-3521-4","volume":"98","author":"K Makishima","year":"2019","unstructured":"Makishima K, Obara N, Ishitsuka K, Sukegawa S, Suma S, Kiyoki Y, et al. High efficacy of eculizumab treatment for fulminant hemolytic anemia in primary cold agglutinin disease. Ann Hematol. 2019;98(4):1031\u20132.","journal-title":"Ann Hematol"},{"key":"208_CR106","doi-asserted-by":"crossref","unstructured":"Neave L, Wilson AJ, Lissack M, Scully M. Severe refractory idiopathic warm autoimmune haemolytic anaemia responsive to complement inhibition with eculizumab. BMJ Case Rep. 2018;11(1):e226429.","DOI":"10.1136\/bcr-2018-226429"},{"issue":"3","key":"208_CR107","first-page":"149","volume":"31","author":"J Schwartz","year":"2016","unstructured":"Schwartz J, Padmanabhan A, Aqui N, Balogun RA, Connelly-Smith L, Delaney M, et al. Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the writing Committee of the American Society for apheresis: the seventh special issue. J Clin Apher. 2016 Jun;31(3):149\u201362.","journal-title":"J Clin Apher"},{"key":"208_CR108","doi-asserted-by":"publisher","unstructured":"Michalak SS. Autoimmune hemolytic Anemia. In: Gu D, Dupre ME, editors. Encyclopedia of gerontology and population aging. Cham: Springer International Publishing; 2019. 1\u201310. Available from: doi: https:\/\/doi.org\/10.1007\/978-3-319-69892-2_62-1.","DOI":"10.1007\/978-3-319-69892-2_62-1"},{"issue":"3","key":"208_CR109","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1111\/j.1399-3046.2005.00460.x","volume":"10","author":"RP Valentini","year":"2006","unstructured":"Valentini RP, Imam A, Warrier I, Ellis D, Ritchey AK, Ravindranath Y, et al. Sirolimus rescue for tacrolimus-associated post-transplant autoimmune hemolytic anemia. Pediatr Transplant. 2006;10(3):358\u201361.","journal-title":"Pediatr Transplant"},{"issue":"4","key":"208_CR110","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1111\/bjh.13010","volume":"167","author":"M Miano","year":"2014","unstructured":"Miano M, Calvillo M, Palmisani E, Fioredda F, Micalizzi C, Svahn J, et al. Sirolimus for the treatment of multi-resistant autoimmune haemolytic anaemia in children. Br J Haematol. 2014;167(4):571\u20134.","journal-title":"Br J Haematol"},{"issue":"1","key":"208_CR111","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1182\/bloodadvances.2016001412","volume":"1","author":"S Ratnasingam","year":"2016","unstructured":"Ratnasingam S, Walker PA, Tran H, Kaplan ZS, McFadyen JD, Tran H, et al. Bortezomib-based antibody depletion for refractory autoimmune hematological diseases. Blood Adv. 2016;1(1):31\u20135.","journal-title":"Blood Adv"},{"issue":"1","key":"208_CR112","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1111\/bjh.16009","volume":"187","author":"J Fadlallah","year":"2019","unstructured":"Fadlallah J, Michel M, Crickx E, Limal N, Costedoat N, Malphettes M, et al. Bortezomib and dexamethasone, an original approach for treating multi-refractory warm autoimmune haemolytic anaemia. Br J Haematol. 2019;187(1):124\u20138.","journal-title":"Br J Haematol"},{"issue":"1","key":"208_CR113","doi-asserted-by":"publisher","first-page":"e28010","DOI":"10.1002\/pbc.28010","volume":"67","author":"E Even-Or","year":"2020","unstructured":"Even-Or E, Naser Eddin A, Shadur B, Dinur Schejter Y, Najajreh M, Zelig O, et al. Successful treatment with daratumumab for post-HSCT refractory hemolytic anemia. Pediatr Blood Cancer. 2020;67(1):e28010.","journal-title":"Pediatr Blood Cancer"},{"issue":"19","key":"208_CR114","doi-asserted-by":"publisher","first-page":"2550","DOI":"10.1182\/bloodadvances.2018020883","volume":"2","author":"C Schuetz","year":"2018","unstructured":"Schuetz C, Hoenig M, Moshous D, Weinstock C, Castelle M, Bendavid M, et al. Daratumumab in life-threatening autoimmune hemolytic anemia following hematopoietic stem cell transplantation. Blood Adv. 2018;2(19):2550\u20133.","journal-title":"Blood Adv"},{"key":"208_CR115","doi-asserted-by":"crossref","unstructured":"Byrd JC, Wierda WG, Schuh A, Devereux S, Chaves JM, Brown JR, et al. Acalabrutinib monotherapy in patients with relapsed\/refractory chronic lymphocytic leukemia: updated phase 2 results. Blood. 2019;26.","DOI":"10.1182\/blood.2018884940"},{"issue":"4","key":"208_CR116","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/j.clml.2013.02.022","volume":"13","author":"K Nader","year":"2013","unstructured":"Nader K, Patel M, Ferber A. Ofatumumab in rituximab-refractory autoimmune hemolytic anemia associated with chronic lymphocytic leukemia: a case report and review of literature. Clin Lymphoma Myeloma Leuk. 2013;13(4):511\u20133.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"23","key":"208_CR117","doi-asserted-by":"publisher","first-page":"4783","DOI":"10.1182\/blood-2010-06-291831","volume":"116","author":"D G\u00f3mez-Almaguer","year":"2010","unstructured":"G\u00f3mez-Almaguer D, Solano-Genesta M, Tar\u00edn-Arzaga L, Herrera-Garza JL, Cant\u00fa-Rodr\u00edguez OG, Guti\u00e9rrez-Aguirre CH, et al. Low-dose rituximab and alemtuzumab combination therapy for patients with steroid-refractory autoimmune cytopenias. Blood. 2010;116(23):4783\u20135.","journal-title":"Blood."},{"issue":"12","key":"208_CR118","doi-asserted-by":"publisher","first-page":"eaax9586","DOI":"10.1126\/sciadv.aax9586","volume":"5","author":"LJ Blumberg","year":"2019","unstructured":"Blumberg LJ, Humphries JE, Jones SD, Pearce LB, Holgate R, Hearn A, et al. Blocking FcRn in humans reduces circulating IgG levels and inhibits IgG immune complex-mediated immune responses. Sci Adv. 2019;5(12):eaax9586.","journal-title":"Sci Adv"},{"key":"208_CR119","doi-asserted-by":"publisher","first-page":"406","DOI":"10.3389\/fimmu.2014.00406","volume":"5","author":"JA Sharp","year":"2014","unstructured":"Sharp JA, Whitley PH, Cunnion KM, Krishna NK. Peptide inhibitor of complement C1, a novel suppressor of classical pathway activation: mechanistic studies and clinical potential. Front Immunol. 2014;5:406.","journal-title":"Front Immunol"},{"issue":"26","key":"208_CR120","doi-asserted-by":"publisher","first-page":"4015","DOI":"10.1182\/blood-2014-02-556027","volume":"123","author":"J Shi","year":"2014","unstructured":"Shi J, Rose EL, Singh A, Hussain S, Stagliano NE, Parry GC, et al. TNT003, an inhibitor of the serine protease C1s, prevents complement activation induced by cold agglutinins. Blood. 2014;123(26):4015\u201322.","journal-title":"Blood."},{"issue":"7","key":"208_CR121","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1182\/blood-2012-11-467209","volume":"121","author":"D Wouters","year":"2013","unstructured":"Wouters D, Stephan F, Strengers P, de Haas M, Brouwer C, Hagenbeek A, et al. C1-esterase inhibitor concentrate rescues erythrocytes from complement-mediated destruction in autoimmune hemolytic anemia. Blood. 2013;121(7):1242\u20134.","journal-title":"Blood."},{"key":"208_CR122","doi-asserted-by":"crossref","unstructured":"J\u00e4ger U, D\u2019Sa S, Sch\u00f6rgenhofer C, Bartko J, Derhaschnig U, Sillaber C, et al. Inhibition of complement C1s improves severe hemolytic anemia in cold agglutinin disease: a first-in-human trial. Blood. 2019;133(9):893\u2013901.","DOI":"10.1182\/blood-2018-06-856930"},{"issue":"6","key":"208_CR123","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1182\/bloodadvances.2019001321","volume":"4","author":"G Gelbenegger","year":"2020","unstructured":"Gelbenegger G, Schoergenhofer C, Derhaschnig U, Buchtele N, Sillaber C, Fillitz M, et al. Inhibition of complement C1s in patients with cold agglutinin disease: lessons learned from a named patient program. Blood Adv. 2020;4(6):997\u20131005.","journal-title":"Blood Adv"},{"issue":"22","key":"208_CR124","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1182\/blood.V128.22.1265.1265","volume":"128","author":"MA Gertz","year":"2016","unstructured":"Gertz MA, Qiu H, Kendall L, Saltarelli M, Yednock T, Sankaranarayanan S. ANX005, an inhibitory antibody against C1q, blocks complement activation triggered by cold agglutinins in human disease. Blood. 2016;128(22):1265.","journal-title":"Blood."},{"issue":"17","key":"208_CR125","doi-asserted-by":"publisher","first-page":"4094","DOI":"10.1182\/blood-2008-11-189944","volume":"113","author":"AM Risitano","year":"2009","unstructured":"Risitano AM, Notaro R, Marando L, Serio B, Ranaldi D, Seneca E, et al. Complement fraction 3 binding on erythrocytes as additional mechanism of disease in paroxysmal nocturnal hemoglobinuria patients treated by eculizumab. Blood. 2009;113(17):4094\u2013100.","journal-title":"Blood."},{"issue":"4","key":"208_CR126","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1111\/eci.12419","volume":"45","author":"DC Mastellos","year":"2015","unstructured":"Mastellos DC, Yancopoulou D, Kokkinos P, Huber-Lang M, Hajishengallis G, Biglarnia AR, et al. Compstatin: a C3-targeted complement inhibitor reaching its prime for bedside intervention. Eur J Clin Investig. 2015;45(4):423\u201340.","journal-title":"Eur J Clin Investig"},{"issue":"2","key":"208_CR127","doi-asserted-by":"publisher","first-page":"e57","DOI":"10.3324\/haematol.2019.216028","volume":"105","author":"I Baas","year":"2020","unstructured":"Baas I, Delvasto-Nu\u00f1ez L, Ligthart P, Brouwer C, Folman C, Reis ES, et al. Complement C3 inhibition by compstatin Cp40 prevents intra- and extravascular hemolysis of red blood cells. Haematologica. 2020;105(2):e57\u201360.","journal-title":"Haematologica."},{"key":"208_CR128","doi-asserted-by":"crossref","unstructured":"Szil\u00e1gyi K, Hajd\u00fa I, Flachner B, L\u0151rincz Z, Balczer J, G\u00e1l P, et al. Design and selection of novel C1s inhibitors by in Silico and in vitro approaches. Molecules. 2019;24(20):3641.","DOI":"10.3390\/molecules24203641"}],"container-title":["Immunity &amp; Ageing"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12979-020-00208-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12979-020-00208-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12979-020-00208-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,20]],"date-time":"2020-11-20T05:25:25Z","timestamp":1605849925000},"score":1,"resource":{"primary":{"URL":"https:\/\/immunityageing.biomedcentral.com\/articles\/10.1186\/s12979-020-00208-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,20]]},"references-count":128,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["208"],"URL":"https:\/\/doi.org\/10.1186\/s12979-020-00208-7","relation":{},"ISSN":["1742-4933"],"issn-type":[{"value":"1742-4933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,20]]},"assertion":[{"value":"8 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"38"}}